To improve the lives of millions suffering from neurodegeneration.
Who are we?
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s disease and ischemic stroke. Bolden’s research facility is located in Cambridge, MA, and its corporate headquarters is located in Providence, RI.
Neurogenesis has been extensively studied in animals, and is believed to play an important role in learning and memory. Diminished neurogenesis can contribute to cognitive dysfunction and memory impairment, and this phenomenon is observed in multiple neurodegenerative diseases and neurological conditions. In addition, neurogenesis has been implicated as important for functional recovery following traumatic brain injury and ischemic stroke.